Alzheimer's Disease

Neurotechnology company, Grey Matter Neurosciences, announced it secured $14 million in seed financing, which will be used to develop an ultrasound headset for individuals with Alzheimer's disease and test that device in clinical trials.

The analytical tool can also predict demographics and understand personality traits by understanding brain activity patterns.

The AI avatar, Liv, can hold conversations in real-time to provide individuals with dementia and Alzheimer's with resources and aid.

The app, Elevmi, uses AI to facilitate caregivers' management of patients with Alzheimer's Disease.  

It is making further moves to penetrate the Southeast Asian market.

The company will use the funds to advance the study of its neuromodulation device intended to treat Alzheimer's disease.

A clinical trial has shown that it can predict AD progression with 88% and 84% accuracy in American and Japanese patients, respectively.

Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.

The startup will now move onto a larger pivotal trial of the neuromodulation therapy, which received a Breakthrough Device Designation from the FDA in January.

The research project will be conducted using the Apple Watch and iPhone, and is set to begin during 2021.